Skip to content
Open access

IL-1β signaling on dendritic cells expands tumor-specific T cells to overcome immune checkpoint blockade resistance.

Nov 2026 · Molecular Therapy · 0 citations
Medicine

Abstract

Immune checkpoint blockade (ICB) therapy benefits only a subset of patients, and the role of non-T cells in ICB responses remains unclear. IL-1β has been reported to conduct controversial roles in antitumor immunity and ICB responsiveness. Here we show that IL-1β signaling is indispensable for the response to ICB therapy and for intratumoral tumor-specific CD8+ T cells. We hypothesized that ICB resistance is attributed to limited IL-1β inside tumor microenvironment (TME). We engineered mesenchymal stromal cells for the tumor-targeted inducible production of IL-1β-Fc (IL1βFc-EMSC) to study how this cytokine induces antitumor immunity inside the TME. Mechanistically, IL1βFc-EMSC treatment expands CD8+ T cells including Tcf1+PD1+ progenitor exhausted CD8+ T cells (Tpex) in the TME and enhances tumor-specific CD8+ T cell activation. MyD88 signaling in dendritic cells (DCs) by IL-1β might trigger type I IFN that are essential for intratumoral CD8+ T cell restimulation and systemic antitumor responses to eradicate both primary and distal tumors. Moreover, IL1βFc-EMSC treatment induced TIL reinvigoration overcomes ICB resistance in advanced tumors. Clinically, we uncovered a significant association between the formation of a spatially organized IL-1β-cDC1-Tpex axis and ICB responsiveness. Overall, tumor targeting IL-1β reshapes the TME by bridging innate and adaptive immunity to overcome ICB resistance.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.